NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

子宮內膜癌症 - 至2030年的流行病學預測

Endometrial Cancer - Epidemiology Forecast to 2030

出版商 GlobalData 商品編碼 1005553
出版日期 內容資訊 英文 42 Pages
訂單完成後即時交付
價格
子宮內膜癌症 - 至2030年的流行病學預測 Endometrial Cancer - Epidemiology Forecast to 2030
出版日期: 2021年05月10日內容資訊: 英文 42 Pages
簡介

子宮內膜癌症,是子宮癌症中最常見的,從子宮的內薄膜發生。子宮內膜癌症,與雌激素等級上升的關聯性高,常見於年輕的女性,體脂多的女性,服用外因性雌激素的女性。

主要8個國家市場(美國,法國,德國,義大利,西班牙,英國,日本,加拿大),子宮內膜癌症的診斷病例,預計以1.06%的年度成長率(AGR)擴大,從2020年的12萬883病例到2030年增加到13萬3,690病例。還有歐洲5大市場(5EU:法國,德國,義大利,西班牙,英國)的子宮內膜癌症的診斷案例,預計以1.21%的AGR擴大,從2020年的4萬2,775案例到2030年增加到4萬7,947案例。

本報告提供子宮內膜癌症的相關調查,主要8個國家市場上子宮內膜癌症的風險要素與全球趨勢,流行病學預測及洞察,COVID-19的影響等資訊。

目錄

目錄

第1章 子宮內膜癌症:摘要整理

  • 相關報告
  • 今後的報告

第2章 流行病學

  • 病歷
  • 危險因素和合併症
  • 世界以及到目前為止趨勢
  • 預測調查手法
    • 資訊來源
    • 預測的前提條件與方法
    • 預測的前提條件與方法:子宮內膜癌症的確診的發生案例
    • 診斷時的FIGO各分類:子宮內膜癌症的診斷案例
    • 各類型:子宮內膜癌症的診斷案例
    • 各相關生物標記:子宮內膜癌症的診斷案例
    • 5年確診的子宮內膜癌症的診斷案例
  • 子宮內膜癌症的流行病學預測(2020-2030)
    • 子宮內膜癌症和確診的案例
    • 子宮內膜癌症的各年齡發病病例
    • FIGO各分類:的子宮內膜癌症診斷案例
    • 各類型:子宮內膜癌症的診斷案例
    • 關聯的生物標記伴隨的子宮內膜癌症的確診的案例
    • FIGO各分類:HER2陽性子宮內膜癌症和確診的病例
    • 5年確診的子宮內膜癌症的流行案例
  • 討論
    • 流行病學預測的洞察
    • COVID-19的影響
    • 分析的限制
    • 分析的優勢

第3章 附錄

  • 書志
  • 關於作者
    • 流行病學者
    • 評論者
    • 在治療分析及流行病學的全球董事
    • 在醫療保健營運及策略的全球主要及EVP
  • 諮詢方式

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHCER272-21

Endometrial cancer is the most common form of uterine cancer, arising from the endometrial lining of the uterus. Endometroid endometrial cancer is highly associated with increased estrogen levels, making it more common among young women, women with higher levels of body fat, and in those taking a form of exogenous estrogen.

In the 8MM, the diagnosed incident cases of endometrial cancer are expected to increase from 120,883 cases in 2020 to 133,690 cases in 2030, at an Annual Growth Rate (AGR) of 1.06%. In the five major European markets (5EU: France, Germany, Italy, Spain, and the UK), the diagnosed incident cases of endometrial cancer are expected to increase from 42,775 cases in 2020 to 47,947 cases in 2030, at an AGR of 1.21%. When examining the AGR by individual market, GlobalData forecasts that all markets will see an increase in the diagnosed incident cases of endometrial cancer during the forecast period. As seen in Figure 2, in 2020, there were 483,737 five-year diagnosed prevalent cases of endometrial cancer in the 8MM, which is expected to increase to 547,783 cases by 2030, at an AGR of 1.32%.

Scope

  • The Endometrial Cancer Epidemiology Report provides an overview of the risk factors and global trends of endometrial cancer in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and Canada).
  • It also includes a 10-year epidemiology forecast of the diagnosed incident and five-year diagnosed prevalent cases of endometrial cancer in these markets from 2020-2030. The incident cases are further segmented by age, International Federation of Gynecology and Obstetrics (FIGO) stage at diagnosis (I, II, IIIA, and IV), subtype (endometrioid, clear cell, serous, carcinosarcoma, and other), and associated biomarkers: microsatellite instability (MSI) high, mismatch repair deficiency (MMR-D), polymerase 庰 (POLE ) ultra mutation, MSI hypermutated, copy number low (CN low), copy number high (CN high), programmed death-ligand 1 (PDL-1), and human epidermal growth factor receptor 2 (HER-2) positivity.
  • The endometrial cancer epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to Buy

The Endometrial Cancer Epidemiology series will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global endometrial cancer market.
  • Quantify patient populations in the global endometrial cancer market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for endometrial cancer therapeutics in each of the markets covered.
  • Understand magnitude of endometrial cancer population by stage at diagnosis, subtypes, and mutations.

Table of Contents

Table of Contents

1 Endometrial Cancer: Executive Summary

  • 1.1 Related Reports
  • 1.2 Upcoming Reports

2 Epidemiology

  • 2.1 Disease Background
  • 2.2 Risk Factors and Comorbidities
  • 2.3 Global and Historical Trends
  • 2.4 Forecast Methodology
    • 2.4.1 Sources
    • 2.4.2 Forecast Assumptions and Methods
    • 2.4.3 Forecast Assumptions and Methods: Diagnosed Incident Cases of Endometrial Cancer
    • 2.4.4 Diagnosed Incident Cases of Endometrial Cancer by FIGO Stage at Diagnosis
    • 2.4.5 Diagnosed Incident Cases of Endometrial Cancer by Subtype
    • 2.4.6 Diagnosed Incident Cases of Endometrial Cancer by Associated Biomarker
    • 2.4.7 Five-Year Diagnosed Prevalent Cases of Endometrial Cancer
  • 2.5 Epidemiological Forecast for for Endometrial Cancer (2020-2030)
    • 2.5.1 Diagnosed Incident Cases of Endometrial Cancer
    • 2.5.2 Age-Specific Diagnosed Incident Cases of Endometrial Cancer
    • 2.5.3 Diagnosed Incident Cases of Endometrial Cancer by FIGO Stage
    • 2.5.4 Diagnosed Incident Cases of Endometrial Cancer by Subtype
    • 2.5.5 Diagnosed Incident Cases of Endometrial Cancer with Associated Biomarkers
    • 2.5.6 Diagnosed Incident Cases of Endometrial Cancer with HER2 Positivity by FIGO Stage
    • 2.5.7 Five-Year Diagnosed Prevalent Cases of Endometrial Cancer
  • 2.6 Discussion
    • 2.6.1 Epidemiological Forecast Insight
    • 2.6.2 COVID-19 Impact
    • 2.6.3 Limitations of the Analysis
    • 2.6.4 Strengths of the Analysis

3 Appendix

  • 3.1 Bibliography
  • 3.2 About the Authors
    • 3.2.1 Epidemiologist
    • 3.2.2 Reviewers
    • 3.2.3 Global Director of Therapy Analysis and Epidemiology
    • 3.2.4 Global Head and EVP of Healthcare Operations and Strategy
  • Contact Us

List of Tables

List of Tables

  • Table 1: Risk Factors for Endometrial Cancer
  • Table 2: 8MM, Diagnosed Incident Cases of Endometrial Cancer by Subtype, Women, Ages ≥18 Years, N, 2020

List of Figures

List of Figures

  • Figure 1. 8MM, Diagnosed Incident Cases of Endometrial Cancer, Women, Ages ≥18 Years, 2020 and 2030
  • Figure 2: 8MM, Five-Year Diagnosed Prevalent Cases of Endometrial Cancer, Women, Ages ≥18 Years, N, 2020 and 2030
  • Figure 3: 8MM, Diagnosed Incidence of Endometrial Cancer (Cases per 100,000 population), Women, Ages ≥18 Years, 2020 and 2030
  • Figure 4: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of Endometrial Cancer
  • Figure 5: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of Endometrial Cancer by FIGO Stage
  • Figure 6: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of Endometrial Cancer by Subtype
  • Figure 7: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of Endometrial Cancer with Associated Biomarker
  • Figure 8: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of Endometrial Cancer with HER2 Positivity by FIGO Stage
  • Figure 9: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of Endometrial Cancer with HER2 Positivity by FIGO Stage
  • Figure 10: Diagnosed Incident Cases of Endometrial Cancer, 8MM, Women, Ages ≥18 years, 2020
  • Figure 11: 8MM, Diagnosed Incident Cases of Endometrial Cancer by Age, Women, N, 2020
  • Figure 12: 8MM, Diagnosed Incident Cases of Endometrial Cancer by FIGO Stage, Women, Ages ≥18 Years, N, 2020
  • Figure 13: 8MM, Diagnosed Incident Cases of Endometrial Cancer with Associated Biomarker, Women, Ages ≥18 Years, N, 2020
  • Figure 14: 8MM, Diagnosed Incident Cases of Endometrial Cancer with HER2 Positivity by FIGO Stage, Women, Ages ≥18 Years, N, 2020
  • Figure 15: 8MM, Five-Year Diagnosed Prevalent Cases of Endometrial Cancer, Women, Ages ≥18 Years, N, 2020